



創美·CH'MEI

Charmacy Pharmaceutical Co., Ltd.

創美藥業股份有限公司

(A joint stock limited liability company incorporated in the People's Republic of China)

(於中華人民共和國註冊成立之股份有限公司)

(Stock Code 股份代號: 2289)

## NOTIFICATION LETTER 通知信函

28 April 2026

Dear Shareholder(s) <sup>(Note 1)</sup>,

**Charmacy Pharmaceutical Co., Ltd. (the "Company")**

**– Notice of Publication of 2025 Annual Report, Circular and Form of Proxy of 2025 Annual General Meeting ("Current Corporate Communications")**

The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at [www.chmyy.com](http://www.chmyy.com) (the "Company Website") and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at [www.hkexnews.hk](http://www.hkexnews.hk) (the "HKEx Website").

Shareholders who for any reason have difficulty in accessing the Current Corporate Communications posted on the Company Website, please send your request (specifying your name, address and request) by email at [Charmacy.ecom@computershare.com.hk](mailto:Charmacy.ecom@computershare.com.hk) or by notice in writing to the Company's H share registrar, Computershare Hong Kong Investor Services Limited (the "H Share Registrar") at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. The Company will upon receipt of your request send the Current Corporate Communications to you in printed form free of charge.

Shareholders are encouraged to provide their email address to receive Actionable Corporate Communications <sup>(Note 2)</sup> of the Company. Shareholders may provide their email address by scanning the personalised QR code printed on the enclosed Reply Form (see Option 1) or completing the enclosed Reply Form and returning it to the H Share Registrar by post or emailing it to [Charmacy.ecom@computershare.com.hk](mailto:Charmacy.ecom@computershare.com.hk) (see Option 2). If you still wish to receive printed versions of future Corporate Communications, please indicate this on the Reply Form and return it using the mailing label at the bottom (no stamp is needed if posted in Hong Kong). Please refer to the notification letter on Arrangement of Electronic Dissemination of Corporate Communications sent by the Company dated 2 April 2024 which is available on the Company Website and the HKEx Website.

Should you have any queries relating to this letter, please contact the Company at (86)75488109272 during business hours from 9:00 a.m. to 5:30 p.m. (Hong Kong time), Monday to Friday, excluding Hong Kong public holidays.

By order of the Board  
Charmacy Pharmaceutical Co., Ltd.  
**Yan Jingbin**  
Chairman

*Note 1 This letter is being sent to the registered shareholders of the Company, whose names appear on the register of members of the Company. If you have sold or transferred your shares in the Company, please disregard this letter and the Reply Form on its reverse side.*

*Note 2 Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.*

各位股東 <sup>(附註 1)</sup>:

**創美藥業股份有限公司 (「本公司」)**

**—2025 年報、2025 年度股東會通函及代表委任表格 (「本次公司通訊文件」) 之刊發通知**

本公司的本次公司通訊文件中、英文版本已上載於本公司網站 [www.chmyy.com](http://www.chmyy.com) (「本公司網站」) 及香港聯合交易所有限公司 (「聯交所」) 網站 [www.hkexnews.hk](http://www.hkexnews.hk) (「香港交易所網站」), 歡迎瀏覽。

股東若因任何理由以致在瀏覽本公司網站上的本次公司通訊文件時遇有困難, 閣下可將要求 (註明 閣下的姓名、地址及要求) 以電郵方式發送到本公司之電郵地址 [Charmacy.ecom@computershare.com.hk](mailto:Charmacy.ecom@computershare.com.hk) 或以書面方式經本公司的 H 股股份過戶登記處, 香港中央證券登記有限公司 (「H 股股份過戶處」), 地址為香港灣仔皇后大道東 183 號合和中心 17M 樓, 郵寄至本公司。本公司將於收到 閣下的要求後, 向 閣下免費發送有關本次公司通訊文件的印刷本。

本公司鼓勵股東提供電郵地址以收取可供採取行動的公司通訊 <sup>(附註 2)</sup>。請掃描印於隨附回條上之股東專屬二維碼 (請參閱選項 1), 或填妥隨本函所附之回條並郵寄至 H 股股份過戶處或電郵至 [Charmacy.ecom@computershare.com.hk](mailto:Charmacy.ecom@computershare.com.hk) (請參閱選項 2), 以提供股東之電郵地址。如 閣下依然希望收取本公司日後之公司通訊的印刷本, 請在回條上註明, 並使用底部之郵寄標籤交回 (如在香港投寄, 則無須貼上郵票)。詳情請參閱本公司於 2024 年 4 月 2 日發出的《以電子方式發佈公司通訊之安排》的通知信函, 該通知信函可在本公司網站及香港交易所網站上查閱。

如 閣下對本函件有任何疑問, 請於辦公時間星期一至五 (香港公眾假期除外) 上午 9 時正至下午 5 時 30 分 (香港時間) 期間致電本公司 (86)75488109272 查詢。

承董事會命  
創美藥業股份有限公司  
**嚴京斌**  
主席

2026 年 4 月 28 日

*附註 1 本函件收件對象為本公司登記股東。該等人士的姓名載列於本公司股東名冊上。如果 閣下已出售或轉讓所持有的本公司股份, 則無需要理會本函件及其背面的回條。*

*附註 2 可供採取行動的公司通訊指任何涉及及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊。*

